Armata Pharmaceuticals Inc
AMEX:ARMP
Armata Pharmaceuticals Inc
Income from Continuing Operations
Armata Pharmaceuticals Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Armata Pharmaceuticals Inc
AMEX:ARMP
|
Income from Continuing Operations
-$426k
|
CAGR 3-Years
75%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Income from Continuing Operations
$4.2B
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Income from Continuing Operations
$6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-8%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Income from Continuing Operations
$5.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
0%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Income from Continuing Operations
-$988.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-3%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Income from Continuing Operations
$4.5B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
15%
|
CAGR 10-Years
29%
|
|
Armata Pharmaceuticals Inc
Glance View
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Marina Del Rey, California and currently employs 72 full-time employees. The firm is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The company has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The firm is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. The company is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The firm is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. The company has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.
See Also
What is Armata Pharmaceuticals Inc's Income from Continuing Operations?
Income from Continuing Operations
-426k
USD
Based on the financial report for Mar 31, 2025, Armata Pharmaceuticals Inc's Income from Continuing Operations amounts to -426k USD.
What is Armata Pharmaceuticals Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
54%
Over the last year, the Income from Continuing Operations growth was 99%. The average annual Income from Continuing Operations growth rates for Armata Pharmaceuticals Inc have been 75% over the past three years , 54% over the past five years .
You don't have any saved screeners yet